The Impact of COVID-19 on Cancer Clinical Trials Conducted by NCI-Designated Comprehensive Cancer Centers.

Diviya Gupta, Shumei Kato, Razelle Kurzrock

Abstract read

In one paragraph

Article in Journal of immunotherapy and precision oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it

0cells of the map it votes in

6citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

A Two-Stage Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Ec-18 in Altering the Severity and Course of Oral Mucositis Secondary to Chemoradiation Therapy for Squamous Cell Cancers of the Head and Neck.Cancers · 2025
Article
The COVID-19 pandemic as a catalyst for innovation: a regulatory framework to assess fit-for-purpose innovative approaches in clinical research.Trials · 2022
Article
Comorbidity between lung cancer and COVID-19 pneumonia: role of immunoregulatory gene transcripts in highTherapeutic advances in medical oncology · 2022
Article
The immune system, cancer, and pathogens: It takes three to tango!Journal of immunotherapy and precision oncology · 2021
Article
COVID-19 Pandemic and Cancer Clinical Trial Pandemonium: Finding the Silver Lining.Journal of immunotherapy and precision oncology · 2021
Article
Patterns of Enrollment in Cancer Treatment Trials During the COVID-19 Pandemic at National Cancer Institute-Designated Cancer Centers.Cancer journal (Sudbury, Mass.)
Article

4 · The record

Corrections and comments

Commented on by
COVID-19 Pandemic and Cancer Clinical Trial Pandemonium: Finding the Silver Lining.2021

5 · Who and what money

Authors and funding

3 authors.

Diviya GuptaSchool of Medicine, University of California San Diego, La Jolla, CA, USA.

Shumei KatoCenter for Personalized Cancer Therapy and Division of Hematology/Oncology, University of California San Diego Moores Cancer Center, La Jolla, CA, USA.

Razelle KurzrockCenter for Personalized Cancer Therapy and Division of Hematology/Oncology, University of California San Diego Moores Cancer Center, La Jolla, CA, USA.

Funding

VIRAL MALIGNANCYP30CA023100 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DIANE M SIMEONE · 1985 to 2026

$124.9M

NCI NIH HHS P30 CA023100

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

cancer clinical trialsCOVID-19NCI-designated comprehensive cancer centertelemedicinetrial enrollment

Identifiers

PMID34337550

DOI10.36401/jipo-20-30

PMCPMC8320380

What OpenQuestion holds

Textmetadata

LicenceTDM

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.